136 related articles for article (PubMed ID: 31091400)
1. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.
Goodman PJ; Tangen CM; Thompson IM
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091400
[No Abstract] [Full Text] [Related]
2. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Garnick MB
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091399
[No Abstract] [Full Text] [Related]
3. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Stapff MP; Palm S
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091398
[No Abstract] [Full Text] [Related]
4. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
[TBL] [Abstract][Full Text] [Related]
5. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
7. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Goodman PJ; Tangen CM; Darke AK; Lucia MS; Ford LG; Minasian LM; Parnes HL; LeBlanc ML; Thompson IM
N Engl J Med; 2019 Jan; 380(4):393-394. PubMed ID: 30673548
[No Abstract] [Full Text] [Related]
9. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Andriole GL; Guess HA; Epstein JI; Wise H; Kadmon D; Crawford ED; Hudson P; Jackson CL; Romas NA; Patterson L; Cook TJ; Waldstreicher J
Urology; 1998 Aug; 52(2):195-201; discussion 201-2. PubMed ID: 9697781
[TBL] [Abstract][Full Text] [Related]
10. Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
Resnick MJ
J Urol; 2018 Oct; 200(4):689. PubMed ID: 30227567
[No Abstract] [Full Text] [Related]
11. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
12. Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
Kaplan SA
J Urol; 2018 Jan; 199(1):7-8. PubMed ID: 29310201
[No Abstract] [Full Text] [Related]
13. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
Cote RJ; Skinner EC; Salem CE; Mertes SJ; Stanczyk FZ; Henderson BE; Pike MC; Ross RK
Br J Cancer; 1998 Aug; 78(3):413-8. PubMed ID: 9703292
[TBL] [Abstract][Full Text] [Related]
14. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
Mellon JK
Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
[TBL] [Abstract][Full Text] [Related]
15. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
16. Effect of finasteride on risk of prostate cancer: how little we really know.
Rubin MA; Kantoff PW
J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
Stoner E; Round E; Ferguson D; Gormley GJ
J Urol; 1994 May; 151(5):1296-300. PubMed ID: 7512661
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of participants in the prostate cancer prevention trial.
Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
[TBL] [Abstract][Full Text] [Related]
19. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
[TBL] [Abstract][Full Text] [Related]
20. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
